Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy

BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical charact...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Intern Med
Main Authors: Morena, Valentina, Milazzo, Laura, Oreni, Letizia, Bestetti, Giovanna, Fossali, Tommaso, Bassoli, Cinzia, Torre, Alessandro, Cossu, Maria Vittoria, Minari, Caterina, Ballone, Elisabetta, Perotti, Andrea, Mileto, Davide, Niero, Fosca, Merli, Stefania, Foschi, Antonella, Vimercati, Stefania, Rizzardini, Giuliano, Sollima, Salvatore, Bradanini, Lucia, Galimberti, Laura, Colombo, Riccardo, Micheli, Valeria, Negri, Cristina, Ridolfo, Anna Lisa, Meroni, Luca, Galli, Massimo, Antinori, Spinello, Corbellino, Mario
Formato: Artigo
Idioma:Inglês
Publicado em: European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241995/
https://ncbi.nlm.nih.gov/pubmed/32448770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejim.2020.05.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados